The 12 most recent market catalysts affecting $IRON, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92
Morgan Stanley's analyst Sean Laaman maintained an 'Overweight' rating on Disc Medicine (IRON) and slightly raised the price target from $90 to $92. This action signals continued c…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Disc Medicine (IRON) and significantly raised the price target from $83 to $115. This action signals a strong …
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on Disc Medicine (IRON) and raised the price target from $86 to $124. This substantial increase in the price tar…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110
Wedbush analyst David Nierengarten maintained an 'Outperform' rating for Disc Medicine (IRON) and raised the price target from $100 to $110. This action signals continued bullish s…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120
BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Disc Medicine (IRON) and raised the price target from $100 to $120. This action signals increased …
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 95
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
Disc Medicine reported highly positive topline results from its pivotal Phase 3 APOLLO trial for bitopertin, a drug designed to treat EPP and XLP, rare genetic disorders causing se…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170
Cantor Fitzgerald's analyst Kristen Kluska has raised the price target for Disc Medicine (IRON) from $125 to $170 while maintaining an 'Overweight' rating. This upgrade signals a m…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 60
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86
Wells Fargo analyst Derek Archila maintained an Overweight rating on Disc Medicine (IRON) and raised the price target from $79 to $86. This analyst upgrade signals a positive outlo…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $100
Wedbush analyst David Nierengarten maintained an Outperform rating on Disc Medicine (IRON) and raised the price target from $88 to $100. This action indicates a strengthened positi…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Disc Medicine To Present Data From Multiple Clinical Programs At The SOHO Annual Meeting, To Be Held In Houston, Texas, On September 9-12, 2026
Disc Medicine is announcing an upcoming presentation of initial data from its RESTORE-PV trial for DISC-3405 in patients with polycythemia vera at the SOHO Annual Meeting in Septem…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120
HC Wainwright & Co. analyst Douglas Tsao maintained a 'Buy' rating on Disc Medicine (IRON) and raised the price target from $118 to $120. This action indicates a continued bullish …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Disc Medicine Q2 EPS $(1.54) Beats $(1.77) Estimate
Disc Medicine (IRON) announced its Q2 earnings, reporting a loss of $(1.54) per share, which surpassed the analyst consensus estimate of $(1.77). This beat by 12.99% indicates bett…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.